MindWalk Applies HYFT® Technology to Detect Functional Adjacency Linked to Portfolio Risk in AI-Designed Therapeutics
MindWalk (NASDAQ:HYFT) is now covered by analysts at
Weiss Ratings. They set a "sell (d-)" rating on the stock.
MindWalk (NASDAQ:HYFT) was downgraded by analysts at Zacks Research from a "hold" rating to a "strong sell" rating.
MindWalk Validates Platform Precision with Breakthrough Discovery Targeting Pathogenic TDP-43 in Neurodegenerative Disease
REPEAT/MindWalk Advances Universal Influenza Program with a Breakthrough Functional Insight